A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Phase 1 Terminated 53 enrolled MedImmune LLC

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumors and in combination with durvalumab in subjects with solid tumors.

Timeline

Start: 2015-11-04
Primary completion: 2018-10-26
Completion: 2018-10-26

Outcome

Outcome not reported

Stopped (Business): “Company strategy”

Publications

Siu L, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P, Grilley-Olson J, Rook AH, Hollebecque A, Wong RKS, Welsh JW, Wu Y, Morehouse C, Hamid O, Walcott F, Cooper ZA, Kumar R, Ferte C, Hong DS. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 Oct;8(2):e001095. doi: 10.1136/jitc-2020-001095.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	Intravenous
Subject	TELRATOLIMOD	Small molecule	0.005 mg	Other
Subject	TELRATOLIMOD	Small molecule	0.012 mg	Other
Subject	TELRATOLIMOD	Small molecule	0.037 mg	Other
Subject	TELRATOLIMOD	Small molecule	0.055 mg	Other